MedTrace Logo

Clinical Trials

NCT04214249 | ACTIVE_NOT_RECRUITING | PHASE2
49 participants

BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-28
Start Date:
2021-02-17
Completion:
2024-11-27
Conditions
  • Acute Myeloid Leukemia
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • Acute Myeloid Leukemia Post Cytotoxic Therapy
  • Secondary Acute Myeloid Leukemia
Interventions
  • PROCEDURE
  • DRUG
  • BIOLOGICAL
Results Available
NCT04207437 | RECRUITING | NA
16 participants

Daily Hand-Held Vibration Therapy

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-28
Start Date:
2021-12-06
Completion:
2026-09-30
Conditions
  • Neuropathy
  • Cancer
  • Chemotherapeutic Drug - Induced Nephropathy
  • Chemotherapeutic Toxicity
Interventions
  • DEVICE
No Results Yet
NCT04034927 | ACTIVE_NOT_RECRUITING | PHASE2
61 participants

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-28
Start Date:
2019-12-04
Completion:
2021-07-31
Conditions
  • Fallopian Tube Endometrioid Tumor
  • Fallopian Tube High Grade Serous Adenocarcinoma
  • Malignant Ovarian Endometrioid Tumor
  • Ovarian High Grade Serous Adenocarcinoma
  • Platinum-Sensitive Fallopian Tube Carcinoma
  • Platinum-Sensitive Ovarian Carcinoma
  • Platinum-Sensitive Primary Peritoneal Carcinoma
  • Primary Peritoneal High Grade Serous Adenocarcinoma
  • Recurrent Fallopian Tube Carcinoma
  • Recurrent Fallopian Tube Endometrioid Adenocarcinoma
  • Recurrent Ovarian Endometrioid Adenocarcinoma
  • Recurrent Ovarian Serous Adenocarcinoma
  • Recurrent Primary Peritoneal Carcinoma
  • Recurrent Primary Peritoneal Endometrioid Adenocarcinoma
Interventions
  • PROCEDURE
  • DRUG
  • BIOLOGICAL
Results Available
NCT03890237 | ACTIVE_NOT_RECRUITING | NA
4500 participants

GAGE Act With Her-Ethiopia Evaluation

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-28
Start Date:
2019-03-01
Completion:
2025-12-31
Conditions
  • Adolescent Behavior
  • Gender
Interventions
  • BEHAVIORAL
No Results Yet
NCT03351803 | ACTIVE_NOT_RECRUITING
5412 participants

BRCA Founder OutReach (BFOR) Study

Study Type:
OBSERVATIONAL
Last Updated:
2026-05-28
Start Date:
2017-11-10
Completion:
2027-05-10
Conditions
  • BRCA1 Mutation
  • BRCA2 Mutation
Interventions
  • OTHER
No Results Yet
NCT03017820 | RECRUITING | PHASE1
99 participants

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-28
Start Date:
2017-04-04
Completion:
2028-12-31
Conditions
  • B-Cell Non-Hodgkin Lymphoma
  • Histiocytic and Dendritic Cell Neoplasm
  • Myelodysplastic Syndrome
  • Previously Treated Myelodysplastic Syndrome
  • Recurrent Adult Acute Myeloid Leukemia
  • Recurrent Anaplastic Large Cell Lymphoma
  • Recurrent Angioimmunoblastic T-Cell Lymphoma
  • Recurrent Mycosis Fungoides
  • Recurrent Plasma Cell Myeloma
  • Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
  • Recurrent T-Cell Non-Hodgkin Lymphoma
  • Refractory Acute Myeloid Leukemia
  • Refractory Anaplastic Large Cell Lymphoma
  • Refractory Angioimmunoblastic T-Cell Lymphoma
  • Refractory Mycosis Fungoides
  • Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
  • Refractory Plasma Cell Myeloma
  • Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
  • Refractory T-Cell Non-Hodgkin Lymphoma
Interventions
  • PROCEDURE
  • DRUG
  • BIOLOGICAL
No Results Yet
Previous
Sorted by latest updates
Next
Showing 40 trials per page